In men with 2 nocturnal voids at baseline , 61 and 49 % of patients with silodosin and placebo had reductions of 1 voids/night , respectively ( p = 0.0003 ) , and significantly more patients with silodosin had < 2 nocturia episodes at study end compared to placebo ( 29.3 vs. 19.0 % ; p = 0.0002 ) .